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1. Introduction 
Native and modified starches have been used in tablets as fillers, binders and disintegrant [1]. They consist of two 
polymers of glucose, i.e., linear amylose and branched amylopectin [2]. In general, native starches are insoluble in water 
but it swells in contact with water and thus has some disintegrating properties. The sustained-release properties of modified 
starches, generally based on solvent-activation, have been intensively investigated, example, pre-gelatinized starch [3], 
cross-linked amylose [4] substituted amylase [5] and short chained amylose (i.e., amylodextrin) [6,7] all have retarded drug 
release from matrix tablets.  
In recent years, a new generation of polymers has been introduced as tablet excipient for the purposes of controlled 
drug release. Different techniques, such as chemical reactions [8], complexation reactions [9] and grafting [10,11] have 
been applied to alter native biopolymers by process modifications or substitutions with other compounds and on molecular 
functional groups. Starches are an interesting group of native biopolymers for these objectives. Native potato starches that 
are chemically modified with steroyl functional groups are defined as starch stearate (SS). As a glucose monomer contains 
three free hydroxyl groups that can be substituted, the average degree of substitution can range from 0 up to 3.0. The 
introduction of steroyl functional groups changes the nature of starch (Stearate) from hydrophilic to more hydrophobic. 
This modification consequently inhibits the characteristic swelling and gel layer formation of native starches. This 
increased hydrophobicity of starch stearate makes it a suitable controlled drug release excipient for tablets.  
Drug release from tablets compressed from modified starches has been studied widely [5, 12- 13]. Besides the 
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characteristic first-order drug release kinetics known for matrix tablets, linear drug releases over time also have been 
reported.[14] In particular, changes in drug release kinetic were related to changes in the physical appearance of a tablet 
during drug dissolution testing. The literature on erodible polymeric delivery systems shows that various transport 
mechanisms simultaneously influence the total drug release rate
 
[15-18]. Basically, for sequential processes the slowest, and 
for parallel processes the fastest step is of main importance. Furthermore, porosity and pore size describing the initial 
matrix structure are also factors that have distinctive contributions to these processes of drug release from substituted 
polymer matrix tablets. 
The most significant variables that affect the release of drugs from the starch stearate matrix are the particle and 
powder properties of starch stearate, tablet properties (i.e. porosity), the ratio of drug and starch stearate concentrations in 
the formulation, and the physicochemical nature of the drug [19-22]. The drug release profile can be governed by adjusting 
these factors. 
Thus main aim of this study was to investigate the effects of drug-excipient interactions in a powder blend and 
resulting tablet structure on drug release kinetics. The physical behavior in a liquid medium of tablets with starch stearate 
(degree of substitution 2.7) as a hydrophobic, inert matrix former was related to drug release mechanisms. 
 
2. Materials and methods 
2.1 Materials 
SSs were prepared by esterification of potato starch with Steroyl chloride. Verapamil HCl (VH) and Diclofenac 
sodium (DS) were gifted by Alembic Pharma Ltd., India and Zim Laboratories, Nagpur, India respectively. Microcrystalline 
cellulose, Dicalcium phosphate and Lactose monohydrate were obtained from Chemfield Pharma, India, Finar Chemicals, 
Ahmedabad, India and Loba Chemie Pvt. Ltd., India respectively. All other chemicals used were of analytical grade and 
used as received. 
2.2 Polymer: drug interaction study 
The possible polymer: drug interaction was confirmed by FT-IR study. The samples were prepared by physical 
mixture of polymer, Starch stearate (SS) with drugs (Diclofenac sodium and Verapamil hydrochloride), the spectra obtained 
by FT-IR spectrophotometer (FTIR-8001, Shimadzu, Japan) operated with omnic software on sample prepared by KBr 
press pellet technique were examined. 
2.3 Preparation of matrix tablets 
After preliminary laboratory trials, matrix tablets each containing 50 mg drug was prepared by a conventional wet 
granulation technique. The composition of various formulations of the tablets with their codes is listed in Table 1. 
Granulation was done manually with a solution of calculated quantity of SS in sufficient solvent of methylene chloride. The 
wet mass was passed through a 14 mesh sieve and air dried. The dried granules were sized by a 20 mesh sieve, mixed and 
lubricated. Granules thus obtained were compressed into tablets on ten station rotary compression machine (Chamunda 
Machineries, Ahmedabad, India) at a constant compression force using 8 mm punches. Prior to compression, granules were 
evaluated for their flow and compressibility characteristics.  
Table No 1. Composition of Tablet Formulations 
Ingredients (%) F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 
VH 20 20 20 20 20 20 20 20 - - - - - 
DS - - - - - - - - 20 20 20 20 20 
MCC 63 58 48 - - 24 24 - 63 58 48 - - 
LM - - - 48 - 24 - 24 - - - 48 - 
DCP - - - 
 
48 
 
24 24 - - - - 48 
SS 15 20 30 30 30 30 30 15 20 30 30 30 30 
MS 2 2 2 2 2 2 2 2 2 2 2 2 2 
*VH- Verapamil hydrochloride, DS- Diclofenac sodium, MCC- Microcrystalline cellulose, DCP- Dicalcium phosphate, 
LM- Lactose monohydrate, MS- Magnesium stearate, SS-starch stearate. 
 
2.4 Evaluation of granules 
2.4.1 Determination of Angle of repose: 
The angle of repose was determined by fixed height funnel method, where a funnel is fixed to a stand and it is 
adjusted up to the required height and pellets are filled into the funnel by closing the tip of the funnel with finger
 
[23-25]. 
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After filling the funnel completely the finger is released and pellets are allowed to pass until they form a pile. Then the 
angle of repose is calculated as shown in Table 2. 
2.4.2 Determination of bulk density 
The bulk density was measured by taking 50 g of into 100 ml calibrated measuring cylinder and subjected to 3 
taps, then bulk density was calculated by calculating the volume occupied then dividing weight by volume 
2.4.3 Determination of Tapped density: 
The tapped density was measured by dividing weight by volume but the final volume was measured after tapping 
the cylinder for fixed number of tappings as per the pharmacopeia guidelines until a constant volume was obtained using 
tap density apparatus (Electrolab®, India) the results are  shown in Table 2.  
2.4.4 Compressibility index 
Compressibility index was determined after determining bulk and tapped density by using the following formula 
                                               Carr’s index (%) = [(TD-BD)] / TD x 100 
2.4.5 Hausner’s ratio  
Hausner’s ratio was determined by using the following formula 
                                               Hausner’s ratio = TD / LD 
 
Table No 2. Evaluation of granules 
Formulations 
Angle of 
response(𝛳) 
Bulk 
density(g/ml) 
Tapped  density 
(g/ml) 
Carr’s index 
(%) 
Hausner’s 
ratio 
F1 21.41 0.46 0.51 9.80 1.10 
F2 20.6 0.38 0.44 13.64 1.15 
F3 25.32 0.44 0.47 10.64 1.06 
F4 25.97 0.47 0.57 17.54 1.21 
F5 25.68 0.57 0.66 13.64 1.15 
F6 23.80 0.43 0.51 15.69 1.18 
F7 25.23 0.44 0.47 10.64 1.06 
F8 24.44 0.57 0.67 14.93 1.17 
F9 26.56 0.43 0.47 8.51 1.09 
F10 26.07 0.42 0.47 10.64 1.11 
F11 26.83 0.51 0.57 10.53 1.11 
F12 25.45 0.46 0.52 11.54 1.13 
F13 25.20 0.59 0.65 9.23 1.10 
 
2.5 Evaluation of tablets: 
2.5.1 Tablet thickness:  
Tablet thickness was determined using a screw gauge micrometer and the limit and the variation should be ±5% of 
the standard value. 
2.5.2 Tablet Hardness: 
The resistance of the tablet to chipping, abrasion or breakage under conditions of storage, transportation and 
handling before usage depends on its hardness (Lachman, 1991). The hardness of the formulated tablets were determined 
using Monsanto hardness tester. 
2.5.3 Friability: 
Friability was measured using Roche friabilator (Campbell Electronics, Mumbai, India). It evaluates the ability of 
the tablet to with stand abrasion during packaging, handling and shipping. Required quantities of tablets were taken based 
on their weight following the procedure according to USP. Then the tablets were placed in the apparatus and allowed to 
rotate for 100rpm (4min with 25rpm) [26-28]. Then the tablets were weighed and the loss in weight before rotation and 
after rotation indicates the friability losses. The generally accepted range is the friability losses should be between 0.5-1.0 
% and the results are tabulated in Table 3. 
2.5.4 Drug content: 
The drug content was determined by crushing the tablets and taking sample equivalent to 100.0 mg from each 
formulation [29-32]. The sample was transferred to 100.0 mL flask and diluted to volume with the pH 6.8 phosphate buffer 
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and sonicated for 20 minutes (PCi Mumbai, India), centrifuged and filtered and the drug content was determined from 
absorbance at its lambda max using UV spectrometer (Shimadzu-UV-150-02 Kyoto, Japan)  
2.5.5 In Vitro dissolution studies: 
The in vitro dissolution study was carried out in using USP XXIV dissolution test apparatus type II (Veego 
Scientifics, Mumbai) at 75 rpm. The dissolution medium consisted of 900 ml of pH 6.8 phosphate buffer 9 h maintained at 
37 ± 0.5 ⁰C. An aliquot (10 ml) was withdrawn at specific time intervals and drug content was determined by analyzing the 
samples with UV/VIS spectrophotometer (1700 Shimadzu, Japan) at 276 nm for DS and 278 nm for VH. 
Table No 3: Evaluation of tablets 
Formulations Thickness (mm) Hardness (kg/cm
2
) Friability (%) Drug content (%) 
F1 5.05± 0.003 3.47± 0.252 0.23 98.20 ± 0.572 
F2 5.02± 0.001 3.17± 0.289 0.23 97.89± 0.360 
F3 5.05± 0.004 3.47± 0.351 0.19 99.10± 0.354 
F4 5.02± 0.002 3.37± 0.321 0.22 98.06± 0.459 
F5 5.01± 0.006 3.17± 0.289 0.22 98.73± 0.800 
F6 5.52± 0.003 3.60± 0.265 0.17 98.77 ± 1.102 
F7 5.53± 0.004 3.47± 0.252 0.21 97.40± 0.780 
F8 5.54± 0.002 3.10± 0.100 0.24 98.20± 0.633 
F9 5.52± 0.001 3.33± 0.351 0.18 98.78± 0.234 
F10 5.54± 0.001 4.20± 0.200 0.19 98.98± 0.472 
F11 5.50± 0.004 4.17± 0.289 0.23 99.17± 0.471 
F12 5.53± 0.002 3.40± 0.100 0.21 99.44± 1.064 
F13 5.51± 0.005 3.53± 0.058 0.27 98.80± 0.580 
2.5.6 Drug release kinetic model: 
To describe the kinetics of drug release from the tablets, mathematical models zero order, first order, Higuchi, 
Hixon-crowell, Korsmeyer-Peppas were used. The criterion for selecting the best fit model was chosen on the basis of the 
goodness fit test. Equations previously stated were used to determine the best fit model for release kinetics [16, 33-35].  
 
3. Results and Discussion 
3.1 The FT-IR spectra of polymer:  
Drug does not show any additional peaks. This indicates that actives used in the studies are compatible with the 
polymer i.e. starch stearate (Fig. 1). The granules of different formulations prepared were evaluated with respect to angle of 
repose, bulk density (BD), tapped density (TD) and compressibility index (Table 2). The granules exhibited angle of repose 
below 27° indicating good flow properties [35-38]. Compressibility index values were in the range of 9.23 to 17.54 %. The 
results of BD and TD ranged from 0.38 to 0.57 g/ml and 0.44 to 0.67 g/ml respectively. The thickness of all the tablets was 
in between 5.008 to 5.537 mm. Drug content was found to be uniform among different batches of the tablets and ranging 
from 97.69% to 99.45%. All the physical parameters of the tablets were well within the range.   
 
Fig. 1 FT-IR spectra of Starch stearate, drugs and with combination. A, SS; B, VH; C, SS:VH; D, DS, E, SS:DS. 
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3.2 Effect of concentration of polymer on drug release: 
Dissolution profiles shown that with increase in polymer concentration, drug release was decreased. The drug 
release from F1, F2, F3, F9, F10 and F11 after 8h was found to be 94.12%, 86.10%, 81.60%, 39.67%, 32.12% and 25.08% 
respectively shown in Fig. 2 and 5. 
 
Fig. 2 Comparative drug release profile of F1 to F3 
 
Fig. 5 Comparative drug release profile of F9 to F11 
 
3.3 Effect of drug properties on drug release 
As observed from the cumulative drug release data, hydrophobic drug (DS) was more sustained than hydrophilic 
drug (VH). Drug release from F3 and F11 after 8h was 81.605 and 25.08% respectively. 
3.4 Effect of excipient on drug release 
Different excipients such as MCC, lactose and DCP were used for studying their effect on drug release. It was 
noticed that DCP sustained drug release more than others when used alone. After 8h, % drug release from F5 and F13 was 
49.86% and 24.19% respectively. When lactose was used alone with hydrophobic drug (F12), drug release increased 
(48.81%). This may be due to formation of pores during the drug release. Effect of combination of excipients in equal 
proportion was also studied on hydrophilic drug and it was observed that combining the DCP and lactose (F8) sustain more 
i.e. 42.62%. Comparison of drug release effects of excipients both alone and in combination is shown in fig 2 to 6. 
 
 
Fig. 3: Comparative drug release profile of F3 to F5 
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Fig. 4 Comparative drug release profile of F3 to F8 
 
Fig. 6 Comparative drug release profile of F11 to F13 
3.5 Drug release kinetics: 
Dissolution profiles were used to asses differences between tablet formulations and to demonstrate the versatility 
of Drug/SS drug-delivery systems. In general, drug release from formulation containing 30% SS concentration was more 
sustained than other once [39-40]. Drug release parameters of different formulations are given in Table 4. 
Table No 4: Drug release kinetics 
Formulation Best Fit model N R 
F1 First order 0.763 0.983 
F2 Korsmeyer-peppas 0.801 0.972 
F3 Zero order 0.740 0.986 
F4 Korsmeyer-peppas 0.576 0.994 
F5 Higuchi 0.561 0.995 
F6 Higuchi 0.517 0.997 
F7 Korsmeyer-peppas 0.559 0.998 
F8 Higuchi 0.577 0.996 
F9 Hixon.Crowell 0.858 0.996 
F10 Korsmeyer-peppas 0.820 0.996 
F11 Korsmeyer-peppas 0.765 0.999 
F12 Higuchi 0.475 0.990 
F13 Higuchi 0.627 0.988 
 
4. Conclusion 
Starch stearate was shown to be a suitable material to control the release of both hydrophilic and hydrophobic 
drug. This study further confirmed that diffusion was the predominant release mechanism, as the n value of different 
formulations is less than 0.89.  
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